Sugi Predict

Sugi Predict / Targets / PSMB11

PSMB11

Proteasome subunit beta type-11 · A5LHX3 · PSMB11 on Sugi Atlas →

23,632 patent compounds predicted against PSMB11, 16,221 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL605949 SCHEMBL605949 0.54 15/20
SCHEMBL607010 SCHEMBL607010 0.56 12/20
SCHEMBL609327 SCHEMBL609327 0.55 12/20
SCHEMBL607553 SCHEMBL607553 0.54 12/20
SCHEMBL606932 SCHEMBL606932 0.53 12/20
SCHEMBL608381 SCHEMBL608381 0.53 12/20
SCHEMBL609081 SCHEMBL609081 0.52 12/20
SCHEMBL606926 SCHEMBL606926 0.52 12/20
SCHEMBL606344 SCHEMBL606344 0.51 12/20
SCHEMBL606616 SCHEMBL606616 0.51 12/20
SCHEMBL1327404 SCHEMBL1327404 0.50 12/20
SCHEMBL607035 SCHEMBL607035 0.61 11/20
SCHEMBL609733 SCHEMBL609733 0.60 11/20
SCHEMBL609324 SCHEMBL609324 0.60 11/20
SCHEMBL605158 SCHEMBL605158 0.59 11/20
SCHEMBL606315 SCHEMBL606315 0.59 11/20
SCHEMBL609290 SCHEMBL609290 0.57 11/20
SCHEMBL607972 SCHEMBL607972 0.55 11/20
SCHEMBL608782 SCHEMBL608782 0.54 11/20
SCHEMBL609278 SCHEMBL609278 0.54 11/20

Clinical trials — most relevant to PSMB11 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease PHASE4UNKNOWN
Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors on Sarcopenia in Hemodialysis Patients PHASE4NOT_YET_RECRUITING
A Study of GSK2110183 in Subjects With Proteasome Inhibitor Refractory Multiple Myeloma PHASE2WITHDRAWN
Doxorubicin and Bortezomib in Treating Patients With Liver Cancer PHASE2COMPLETED
A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma PHASE2COMPLETED
Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors PHASE2COMPLETED
Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes PHASE2UNKNOWN
Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers PHASE2NOT_YET_RECRUITING
The Effect of Roxadustat on Renal Oxygenation in Diabetes Nephropathy PHASE2NOT_YET_RECRUITING
Nelfinavir as Bortezomib-sensitizing Drug in Patients With Proteasome Inhibitor-nonresponsive Myeloma PHASE2COMPLETED
Relapsed and/or Refractory Non-Hodgkin Lymphoma Study PHASE2WITHDRAWN
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck PHASE1COMPLETED
Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma PHASE1COMPLETED
Extended Infusion Carfilzomib on a Weekly Schedule in Patients With Advanced Solid Tumors PHASE1COMPLETED
Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer PHASE1COMPLETED
Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neuroblastoma PHASE1COMPLETED
GO-203-2C + Bortezomib For Relapsed Or Refractory MM PHASE1WITHDRAWN
A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple Myeloma PHASE1COMPLETED
Evaluation of Proteasome as a Marker of Hepatocellular Carcinoma in Cirrhotic Patients Following Curative Treatment nanUNKNOWN
Low Dose Melphalan and Bortezomib for AML and High-Risk MDS nanCOMPLETED
Cardiovascular Complications of Carfilzomib Treatment nanUNKNOWN
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors nanNOT_YET_RECRUITING
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis nanUNKNOWN
The Pathophysiology of Bortezomib Induced Peripheral Neuropathy nanUNKNOWN
Impact of O6-methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation and MGMT Expression on Dacarbazine Treated Sarcoma Patients (MGMT) nanUNKNOWN
Relationship Between Nutritional State and Respiratory Muscle Weakness in Adult Patients With Bronchietasis nanUNKNOWN
Mitochondrial Activity and Myosteatosis in the Cachexia of Cancers of the Upper Aerodigestive Tract nanUNKNOWN
Biomarkers in Tumor Samples From Younger Patients With Neuroblastoma nanCOMPLETED
The PREServation of MUScle Function in Critically Ill Patients (PRESMUS) nanUNKNOWN
The Significance of Urine UbA52 In the Diagnosis of Diabetic Nephropathy nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a PSMB11 binder may also engage these)

ProteinNameSimilarity
Q8BG41 — 0.998 Q8BG41 →
P28064 — 0.983 P28064 →
Q3T112 — 0.980 Q3T112 →
Q5W416 — 0.979 Q5W416 →
PSMB8 Proteasome subunit beta type-8 0.978 landscape →
P28063 — 0.977 P28063 →
O43304 — 0.972 O43304 →
P28075 — 0.972 P28075 →
O55234 — 0.970 O55234 →
P34065 — 0.968 P34065 →
Q96KV7 — 0.967 Q96KV7 →
P30656 — 0.967 P30656 →
P70195 — 0.967 P70195 →
PSMB7 Proteasome subunit beta type-7 0.967 landscape →
Q4KM35 — 0.967 Q4KM35 →
A1XQU1 — 0.967 A1XQU1 →
O75064 — 0.966 O75064 →
P54265 — 0.966 P54265 →
PSMB5 Proteasome Macropain subunit MB1 0.966 landscape →
Q86TL0 — 0.966 Q86TL0 →
Q6ZPG2 — 0.966 Q6ZPG2 →
Q5R8S2 — 0.966 Q5R8S2 →
Q8BGV9 — 0.966 Q8BGV9 →
Q8C9A2 — 0.965 Q8C9A2 →
Q99KY4 — 0.965 Q99KY4 →
GAK Cyclin-G-associated kinase 0.965 landscape →
Q3SYT1 — 0.965 Q3SYT1 →
E2RDP2 — 0.965 E2RDP2 →
A7E3S5 — 0.965 A7E3S5 →
Q6ZPE2 — 0.964 Q6ZPE2 →